nach oben

CNS Drugs

Erschienen in:

01.07.2002 | Current Opinion

Hypertension and Hypercholesterolaemia as Risk Factors for Alzheimer’s Disease

Potential for Pharmacological Intervention

verfasst von: Dr Miia Kivipelto, Mikko P. Laakso, Jaakko Tuomilehto, Aulikki Nissinen, Hilkka Soininen

Erschienen in: CNS Drugs | Ausgabe 7/2002

Einloggen, um Zugang zu erhalten

Abstract

This paper focuses on hypertension and hypercholesterolaemia as risk factors for Alzheimer’s disease and, as such, subjects for prevention. The long-term, prospective, population-based studies regarding the relationship between hypertension or hypercholesterolaemia and Alzheimer’s disease, and the clinical studies regarding the association between antihypertensive or lipid-lowering medications and the risk of Alzheimer’s disease, are reviewed. These studies provide evidence to suggest that elevated blood pressure and cholesterol levels earlier in life may have an important role in the development and expression of late-life Alzheimer’s disease. Based on these data, we propose that proper, early interventions aimed at reducing these cardiovascular risk factors may have an impact on the future incidence and prevalence of Alzheimer’s disease.

Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337–42PubMedCrossRef

Breteler MM. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol Aging 2000; 21: 153–60PubMedCrossRef

Viitanen M, Guo Z. Are cognitive function and blood pressure related? Drugs Aging 1997; 11: 165–9PubMedCrossRef

Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141–5PubMedCrossRef

Notkola I-L, Sulkava R, Pekkanen J, et al. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer’s disease. Neuroepidemiology 1998; 17: 14–20PubMedCrossRef

Launer LJ, Ross GW, Petrovitch H, et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49–55PubMedCrossRef

Kivipelto M, Helkala E-L, Laakso MP, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population-based study. BMJ 2001; 322: 1447–51PubMedCrossRef

Morris MC, Scherr PA, Hebert LE, et al. Association of incident Alzheimer’s disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol 2001; 58: 1640–6PubMedCrossRef

Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354–60PubMedCrossRef

10.

Kuusisto J, Koivisto K, Mykkänen L, et al. Association between features of the insulin resistance syndrome and Alzheimer’s diseases independently of apolipoprotein e4 phenotype: cross sectional population based study. BMJ 1997; 315: 1045–9PubMedCrossRef

11.

Romas SN, Tang M-X, Berglund L, et al. ApoE genotype, plasma lipids, lipoproteins, and Alzheimer’s disease in community elderly. Neurology 1999; 53: 517–21PubMedCrossRef

12.

Slooter AJC, Ruitenberg A, van Duijn CM, et al. The effect of apoE on dementia is not through atherosclerois: the Rotterdam Study. Neurology 2000; 54: 2357–8

13.

Jarvik GP, Wijsman EM, Kukull WA, et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case-control study. Neurology 1995; 45: 1092–6PubMedCrossRef

14.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991; 265: 3255–64CrossRef

15.

Prince MJ, Bird AS, Blizard RA, et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s treatment trial of hypertension in older adults. BMJ 1996; 312: 801–5PubMedCrossRef

16.

Forette F, Seux M-L, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–51PubMedCrossRef

17.

Guo Z, Fratiglioni L, Zhu L, et al. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch Neurol 1999; 56: 991–6PubMedCrossRef

18.

in’t Veld BA, Ruitenberg A, Hofman A, et al. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001; 22: 407–12PubMedCrossRef

19.

Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439–43PubMedCrossRef

20.

Wolozin B. Statin-Alzheimer disease association not yet proven [letter]. Arch Neurol 2000; 58: 1023

21.

Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627–31PubMedCrossRef

22.

Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59: 223–7PubMedCrossRef

23.

Marques-Vidal P, Tuomilehto J. Hypertension awareness, treatment and control in the community: is the “rule of halves” still valid? J Hum Hypertens 1997; 11: 213–20PubMedCrossRef

24.

Kastarinen MJ, Salomaa VV, Vartiainen EA, et al. Trends in blood pressure levels and control of hypertension in Finland from 1982 to 1997. J Hypertens 1998; 16: 1379–87PubMedCrossRef

25.

Coca A. Actual blood pressure control: are we doing things right? J Hypertens 1998; 16 Suppl. 1: S45–51

26.

Wyss JM, van Groen T. Neurologic consequences of hypertension and antihypertensive drug therapy. Curr Opin Nephrol Hypertens 1994; 3: 228–35PubMedCrossRef

27.

Braak E, Griffing K, Arai K, et al. Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? Eur Arch Psychiatry Clin Neurosci 1999; 249 Suppl.3: 14–22PubMedCrossRef

28.

Roth T, Richardson GR, Sullivan JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992; 15: 426–32PubMedCrossRef

29.

Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000; 108: 538–47PubMedCrossRef

30.

Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. Clin Pharm 1994; 34: 989–96

31.

Harrison RWS, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994; 37: 231–6PubMedCrossRef

32.

Gengo F, Cwudzinski D, Kinkel P, et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol 1995; 18: 209–14PubMedCrossRef

33.

Santanello NC, Barber BL, Applegate WB, et al. Effects of pharmacologic lipid lowering on health-related quality of life in older persons: results from the cholesterol reduction in seniors program (CRISP) pilot study. J Am Geriatr Soc 1997; 45: 8–14PubMed

34.

Beffert U, Danik M, Krzywkowski P, et al. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer’s disease. Brain Res Rev 1998; 27: 119–42PubMedCrossRef

35.

Simons M, Keller P, Dichgans J, et al. Cholesterol and Alzheimer’s disease: is there a link? Neurology 2001; 57: 1089–93PubMedCrossRef

36.

Skoog I, Kalaria RN, Breteler MMB. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13 Suppl. 3: 106–14CrossRef

37.

Pasquier F, Leys D, Scheltens P. The influence of coincidental vascular pathology on symptomatology and course of Alzheimer’s disease. J Neural Transm Suppl 1998; 54: 117–27

38.

Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer’s disease: the Nun Study. JAMA 1997; 277: 813–7PubMedCrossRef

39.

Sparks DL, Scheff S, Liu H, et al. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 1995; 131: 162–9PubMedCrossRef

40.

Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Neurobiol Aging 2000; 21: 57–62PubMed

41.

Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med 1995; 332: 512–21PubMedCrossRef

42.

Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 5856–61PubMedCrossRef

43.

Kojro E, Gimpl G, Lammich S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase Alzheimer’s disease AM 10. Proc Natl Acad Sci U S A 2001; 98: 5815–20PubMedCrossRef

44.

Haley RW. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol 2000; 57: 1410–2

45.

Wolozin B. A fluid connection: cholesterol and Aβ. Proc Natl Acad Sci U S A 2001; 98: 5371–3PubMedCrossRef

46.

Simons M, Keller P, De Strooper B, et al. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 1998; 95: 6460–4PubMedCrossRef

47.

Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 2001; 8: 890–9PubMedCrossRef

48.

Hartmann T. Cholesterol, Aβ and Alzheimer’s disease. Trends Neurosci 2001; 24(11 Suppl.): S45–8PubMedCrossRef

49.

Sarti C, Kaarisalo M, Tuomilehto J. The relationship between cholesterol and stroke. Drugs Aging 2000; 17: 33–51PubMedCrossRef

50.

Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci 2001; 187:81–9PubMedCrossRef

51.

Locatelli S, Lütjohann D, Schmidt HH-J, et al. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 2002; 59: 213–9PubMedCrossRef

52.

Joseph J, Shukitt-Hale B, Denisova NA, et al. Copernicus revisited: amyloid beta in Alzheimer’s disease. Neurobiol Aging 2001; 22: 131–46PubMedCrossRef

53.

Kalaria RN, Ballard C. Overlap between pathology of Alzheimer’s disease and vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 Suppl. 3: S115–23PubMedCrossRef

54.

Di Iorio A, Lupinetti M, Abate G. Are vascular factors involved in Alzheimer’s disease? Facts and theories. Aging Clin Exp Res 1999; 11: 345–52

55.

Aguero-Torres H, Winblad B. Alzheimer’s disease and vascular dementia: some points of confluence. Ann N Y Acad Sci 2000; 903: 547–52PubMedCrossRef

Titel: Hypertension and Hypercholesterolaemia as Risk Factors for Alzheimer’s Disease
Potential for Pharmacological Intervention
verfasst von: Dr Miia Kivipelto
Mikko P. Laakso
Jaakko Tuomilehto
Aulikki Nissinen
Hilkka Soininen
Publikationsdatum: 01.07.2002
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 7/2002
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200216070-00001

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Hypertension and Hypercholesterolaemia as Risk Factors for Alzheimer’s Disease

Potential for Pharmacological Intervention

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2002

Relapse and Rehospitalisation Rates in Patients with Schizophrenia

Patients’ Subjective Experiences of Antipsychotics

Cholinergic Nicotinic Systems in Alzheimer’s Disease

Cognitive Dysfunction in Multiple Sclerosis

Spotlight on Almotriptan in Migraine

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update Neurologie